Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share

Brokerages expect that ANI Pharmaceuticals Inc (NASDAQ:ANIP) will report $1.09 earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for ANI Pharmaceuticals’ earnings. The highest EPS estimate is $1.11 and the lowest is $1.07. ANI Pharmaceuticals reported earnings per share of $0.90 during the same quarter last year, which indicates a positive year over year growth rate of 21.1%. The business is scheduled to report its next earnings report on Thursday, March 1st.

On average, analysts expect that ANI Pharmaceuticals will report full year earnings of $3.93 per share for the current year, with EPS estimates ranging from $3.90 to $3.95. For the next fiscal year, analysts anticipate that the business will report earnings of $4.67 per share, with EPS estimates ranging from $4.50 to $4.84. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow ANI Pharmaceuticals.

A number of equities analysts recently commented on ANIP shares. TheStreet raised shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Tuesday, November 7th. ValuEngine raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. Canaccord Genuity reaffirmed a “buy” rating on shares of ANI Pharmaceuticals in a research note on Thursday, November 2nd. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $71.00.

ANI Pharmaceuticals (NASDAQ ANIP) traded up $0.18 during trading on Tuesday, reaching $58.69. 193,477 shares of the company were exchanged, compared to its average volume of 117,621. ANI Pharmaceuticals has a 1 year low of $42.23 and a 1 year high of $74.70. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The firm has a market cap of $683.33, a price-to-earnings ratio of 93.16 and a beta of 2.79.

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after buying an additional 35,722 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 25.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock valued at $22,297,000 after buying an additional 85,529 shares during the period. Renaissance Technologies LLC boosted its stake in shares of ANI Pharmaceuticals by 7.0% during the 2nd quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock valued at $13,918,000 after buying an additional 19,400 shares during the period. Northern Trust Corp boosted its stake in shares of ANI Pharmaceuticals by 5.2% during the 2nd quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock valued at $5,285,000 after buying an additional 5,599 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of ANI Pharmaceuticals by 868.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock valued at $5,404,000 after buying an additional 94,002 shares during the period. 53.35% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/06/analysts-anticipate-ani-pharmaceuticals-inc-anip-will-post-earnings-of-1-09-per-share.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply